Recently, the National Joint Procurement Office of Proprietary Chinese Medicines was formally established, which means that the collection of proprietary Chinese medicines has been fully opened
.
This time, 42 proprietary Chinese medicine products from 16 product groups will be collected, and the procurement cycle will be 2 years
.
The progress of proprietary Chinese medicine collection is advancing layer by layer, from the exploratory collection of Provinces and cities such as Qinghai in Shandong, Jinhua in Zhejiang, puyang in Henan, to the collection and collection of proprietary Chinese medicines in 19 provinces such as Hubei, the landing of proprietary Chinese medicines in 6 provinces such as Guangdong, and then to the recent opening of the national procurement of "proprietary Chinese medicines", the industry expects that the entire industry will undoubtedly face a new round of reshuffle
.
From the perspective of the decline in proprietary Chinese medicines collected by provinces and cities and the alliance, the average decline in the varieties to be won fluctuates around 50%, and the industry expects that the decline in this round of collection and collection may be higher than expected, and market competition will intensify
.
Not only proprietary Chinese medicine, but also the collection of Chinese medicine tablets (Chinese medicine formula granules) is also actively explored and promoted at the local level
.
For example, Liaoning, Guangdong, Fujian and other provinces and cities have implemented the hanging net
of traditional Chinese medicine formula granules.
Regarding the impact of the collection of proprietary Chinese medicines on pharmaceutical companies, some pharmaceutical companies said that they were affected in the short term but the overall situation was controllable
.
For example, at the end of August, Crs 39 said in an institutional survey question, "The decline in Chinese medicine injections in the past six months is first because of the impact of the epidemic, and second, it is related to
the implementation of proprietary Chinese medicines.
" At present, the major varieties of Sanjiu traditional Chinese medicine have been included in the collection of two inter-provincial alliances, and even if the collection is expanded and expanded, the impact on the company is relatively controllable
.
”
The collection of Traditional Chinese medicine formula granules and drinking tablets is still in the pilot process
.
CR Sanjiu expects that the drinking tablet business will try
to collect some varieties in some areas.
The number of national standard varieties of traditional Chinese medicine formula granules is limited, and the provincial standard varieties also have certain differences in the provincial standards, so it is expected that there is no large-scale implementation of the conditions for the collection and mining of formula granules in the short term, and it is expected that after the number of national standard varieties reaches a certain scale, the conditions for collection and mining will be more mature
.
In the industry's view, in the short term, the collection of proprietary Chinese medicines will bring about a decline in drug prices, but it will also expand the market share
of related products by exchanging price for volume.
In the long run, the collection of proprietary Chinese medicines will help the standardized development of the industry, improve the quality standard system, and is expected to benefit enterprises
with advantages in raw material supply, product quality and cost control, and continuous R&D investment.
CITIC Securities believes that the state has frequently issued policies to support the development of traditional Chinese medicine and elevate the development plan of traditional Chinese medicine to the national level
.
A large part of Chinese medicine is exclusive, such as 36 of the 53 varieties collected by the Guangdong Provincial Alliance, while Chinese medicine has the attributes of consumer goods and health care products, and has a long-term growth logic
under the aging of the population and consumption upgrading.
The overall demand for the Chinese medicine industry continues to improve
.
The bank recommends a layout from five major directions, including: a head with a strong moat and a high product brand barrier; Enterprises that benefit from the release of formula granules after the reform of the new national standard, as well as enterprises whose main products have pricing power and superimposed price increase logic; Management improvement logic; Incremental logic of innovative chinese medicines in Traditional Chinese medicines; Traditional Chinese medicine service providers, new traditional Chinese medicine diagnosis and treatment leaders, OMO model national layout continues to advance
.
In general, the collection of proprietary Chinese medicines has become normalized, the collection of traditional Chinese medicine tablets is also actively promoting, a new round of reshuffling in the industry is inevitable, for proprietary Chinese medicine enterprises, it is also necessary to actively innovate, increase investment in research and development, and enhance the competitiveness of their own products in order not to be eliminated
.
